"PET-based Imaging Improves Metastases Detection in Biochemically Recurrent Prostate Cancer" - Marilynn Larkin
Gallium-68 prostate-specific membrane antigen positron emission tomography accurately detects metastases in biochemically recurrent prostate cancer, particularly at low prostate-specific antigen levels, researchers say. Ash Tewari, MBBS, MCh, chair of the department of urology at the Mount Sinai Health System said “Ga-68 PSMA PET is still not FDA approved in the United States, but many of us have access to it because of research collaboration, research activity. But in Europe, it is available very easily and I have sent many patients to European institutions that have the largest experience in doing PSMA scans.” He added, "The bottom line is that above a certain PSA level, a gallium PSMA scan is of use because it tells us exactly where the recurrence is happening," he said. "It has a reasonable sensitivity and accuracy and I don't think there is any other test available right now which does as well as this."
— Ashutosh Tewari, MBBS, MCh, Professor, System Chair, Urology, Icahn School of Medicine at Mount Sinai
Additional coverage: M.D. Alert
New AI Tool by Mount Sinai Researchers Could Reshape Prostate Cancer Care
Sep 23, 2024 View All Press Releases
Mount Sinai Receives $4 Million Gift to Support Prostate Health and Urology Department
Oct 28, 2020 View All Press ReleasesMount Sinai Receives $1 Million Grant for Prostate Cancer Research
Dec 05, 2019 View All Press Releases